LONDON--(BUSINESS WIRE)--Apr 30, 2018--Technavio’s latest market research report on the provides an analysis of the most important trends expected to impact the market outlook from 2018-2022. defines an emerging trend as a factor that has the potential to significantly impact the market and contribute to its growth or decline.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180430005771/en/
Technavio has published a new market research report on the global genome editing market from 2018-2022. (Graphic: Business Wire)
According to Technavio market research analysts, the global genome editing market will grow at a CAGR of approximately 16% during the forecast period. The increase in applications of genome editing in therapeutics is a major factor driving the market’s growth.
The prevalence of chronic and infectious diseases such as malaria, tuberculosis, HIV/AIDS, and hepatitis has rapidly increased. Genome editing can provide therapeutic tools for this disease. CRISPR technologies can provide anti-retroviral therapies to inhibit the virus with reduced treatment interventions. For instance, genome editing can target host-dependent factors such as the co-receptor CCR5, thereby preventing the cellular entry of this virus. Hence, the rise in prevalence of diseases increases the demand for novel therapies using genome editing tools, thereby contributing to the growth of the market.
Global initiatives encouraging proteomics research
Research and academic institutions around the globe are collaborating to understand proteins through the exchange of knowledge and molecular biology techniques involved in proteomics research. In 2012, a global project on genome was initiated, which is an ongoing research project. A major organization is facilitating and serving as the mediator in this project. This organization is an international consortium of national proteomics research associations, government researchers, academic institutions, and industry partners.
“The goal of the genome project is to experimentally observe all proteins produced by sequences translated by the human genome. Such projects will increase the use of genome editing tools. CRISPR-Cas9 gene editing tools can be combined with functional proteomics to explore mechanism-based diagnostics and disease interventions,” says a senior analyst at Technavio for research on .
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Global genome editing market segmentation
This market research report segments the global market into the following end-users (biotechnology and pharmaceutical companies, academic institutes and research laboratories, and CROs) and key regions (the Americas, APAC, and EMEA).
In 2017, the biotechnology and pharmaceutical companies segment was the leading revenue contributor to the global genome editing market. The driving factors for this segment are the prevalence of chronic diseases and the increase in the use of genomic editing tools for research on drug discovery.
The Americas was the leading region for the global genome editing market in 2017, accounting for a market share of more than 42%. It was followed by EMEA and APAC. The APAC region is expected to grow steadily when compared with the other two regions.
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180430005771/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH GENETICS INFECTIOUS DISEASES PHARMACEUTICAL
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 04/30/2018 09:53 AM/DISC: 04/30/2018 09:53 AM